Abstract
RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Volume: 9 Issue: 3
Author(s): Gabriel Courties, Jessy Presumey, Isabelle Duroux-Richard, Christian Jorgensen and Florence Apparailly
Affiliation:
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Abstract: RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Export Options
About this article
Cite this article as:
Courties Gabriel, Presumey Jessy, Duroux-Richard Isabelle, Jorgensen Christian and Apparailly Florence, Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (3) . https://dx.doi.org/10.2174/1871523011009030251
DOI https://dx.doi.org/10.2174/1871523011009030251 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease
Current Vascular Pharmacology Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review
Current Rheumatology Reviews Roles of Secreted Phospholipases A<sub>2</sub> in the Mammalian Immune System
Protein & Peptide Letters Suppression of NF-κB Activation By Gentian Violet Promotes Osteoblastogenesis and Suppresses Osteoclastogenesis
Current Molecular Medicine The Role of Extracellular Nucleic Acids in Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Enhanced Proinflammatory State and Autoimmune Activation: a Breakthrough to Understanding Chronic Diseases
Current Pharmaceutical Design A Review of Current Animal Models of Osteoarthritis Pain
Current Pharmaceutical Biotechnology (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Controversies in Anticoagulant Therapy in Vitreo-Retinal Surgery
Current Pharmaceutical Design Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease
Current Drug Targets Anti-inflammatory Activities of Phenoxyphenyl Ureas Mediated by Inhibition of p38 Kinase
Current Enzyme Inhibition High-density Lipoprotein (HDL) Dysfunction and the Future of HDL
Current Vascular Pharmacology Infectious Complications with Anti-TNFα Therapy in Rheumatic Diseases: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) IRAKs: Key Regulatory Kinases of Innate Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design